Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Toxicity due to treatment causes a negative impact on quality of life in breast cancer survivors. Hot flash symptoms, described as intense sensations of heat, sweating and flushing occur in more than 50 % of breast cancer patients taking tamoxifen. We hypothesized that venlafaxine, a selective-norepinephrine reuptake inhibitor drug, was effective for reducing patient-reported hot flash scores among women treated for breast cancer compared to other non-hormonal treatments. We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg once daily or greater) with non-hormonal comparators for the treatment of hot flashes in female breast cancer patients. The primary outcome was hot flash score (derived from patient-reported hot flash severity and frequency) in randomized controlled trials. Standardized mean differences (SMD) were calculated for each study due to variation in the outcome measures. Heterogeneity was determined using I (2) statistics, and publication bias was assessed using a contour funnel plot and Egger's tests. Pooled analyses demonstrated that venlafaxine significantly reduced hot flash scores compared to the trial comparators (overall SMD 2.06; 95% confidence interval (CI) [0.40, 3.72]). There was significant heterogeneity among these studies (I (2) = 98.7%, P < 0.001). Asymmetry in the contour funnel plot suggests the presence of publication bias and a trend towards small study effects (Egge…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.118, 119, 120, 121”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [118]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Heterogeneity was assessed using I(2) statistics, and publication bias was determined using a contour funnel plot and Egger’s tests [27, 28].”
MethodAssessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309 · cited 1×
“Any procedures based on predictable generation of allocation sequences, and potentially transparent attempts to conceal allocation, such as assignment envelopes, which were not opaque or not sealed, were considered inadequate [19].”
BackgroundMeta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
What is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160 · cited 1×
“The analysis was considered to be according to the intention-to-treat principle if all randomized patients were analyzed in the group they were originally allocated to, regardless of the treatment actually received [20].”
MethodJin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951 · cited 1×
“[13] However, paroxetine should be used with caution in women taking tamoxifen because of cytochrome P450 2D6 (CYP2D6) inhibition caused by drug–drug interaction, leading to reduced efficacy of tamoxifen [14, 15].”
BackgroundStearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850 · cited 1×
“However, this class inhibits CYP2D6 and among a cohort of women administered SSRI drugs in combination with tamoxifen there was an increase in breast cancer related morality due to reduced efficacy of tamoxifen [35, 36].”
BackgroundLoprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737 · cited 5×
“[12] Placebo DB, PC, Flexible dosing RCT, TD 229 159 – 158 (69) – – 4”
BackgroundMethodInfluentialSmall study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study
Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A. W. S., Tschannen, B., Altman, D. G., Egger, M., & Juni, P. (2010) · BMJ · doi:10.1136/bmj.c3515 · Cited by 559 · cited 1×
“Heterogeneity was assessed using I(2) statistics, and publication bias was determined using a contour funnel plot and Egger’s tests [27, 28].”
MethodHolmberg, L., & Anderson, H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15493-7 · Cited by 533
Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010) · BMJ · doi:10.1136/bmj.c693 · Cited by 466 · cited 1×
“However, this class inhibits CYP2D6 and among a cohort of women administered SSRI drugs in combination with tamoxifen there was an increase in breast cancer related morality due to reduced efficacy of tamoxifen [35, 36].”
BackgroundMethodologic lessons learned from hot flash studies.
Sloan, J. A., Loprinzi, C. L., Novotny, P. J., Barton, D. L., Lavasseur, B. I., & Windschitl, H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4280 · Cited by 462 · cited 4×
“study where participants were from Europe [16, 21, 24].”
BackgroundInfluentialRance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.003 · Cited by 380 · cited 1×
“The etiology of these symptoms is complex but may be associated with estrogen withdrawal effects on the hypothalamic thermoregulatory center and other neurotransmitters [4, 5].”
BackgroundCouzi, R. J., Helzlsouer, K. J., & Fetting, J. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2737 · Cited by 315 · cited 1×
“endocrine therapy for breast cancer reported hot flash symptoms [1].”
BackgroundPandya, K. J., Raubertas, R. F., Flynn, P. J., Hynes, H. E., Rosenbluth, R. J., Kirshner, J. J., Pierce, H. I., Dragalin, V., & Morrow, G. R. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00004 · Cited by 310 · cited 1×
“One trial comparing clonidine to placebo shown a reduction in hot flash symptoms in breast cancer patients [33].”
BackgroundUpdated tests for small-study effects in meta-analyses
Harbord, R. M., Harris, R. J., & Sterne, J. A. C. (2009) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0900900202 · Cited by 307
Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.
Goldberg, R. M., Loprinzi, C. L., O'Fallon, J. R., Veeder, M. H., Miser, A. W., Mailliard, J. A., Michalak, J. C., Dose, A. M., Rowland, K. M., & Burnham, N. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.155 · Cited by 292 · cited 2×
“A randomized control trial using transdermal administration of clonidine showed benefit in 55 participants compared to placebo [34].”
BackgroundMethodWalker, E. M., Rodriguez, A. I., Kohn, B., Ball, R. M., Pegg, J., Pocock, J. R., Nunez, R., Peterson, E., Jakary, S., & Levine, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5150 · Cited by 228 · cited 5×
“, not significant in the funnel plot [17, 23, 29].”
BackgroundMethodInfluentialStearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J. J., & Hayes, D. F. (2000) · Annals of Oncology · doi:10.1023/a:1008382706068 · Cited by 224
Hot flashes: phenomenology, quality of life, and search for treatment options
Kronenberg, F. (1994) · Experimental Gerontology · doi:10.1016/0531-5565(94)90012-4 · Cited by 217 · cited 1×
“Patients may also experience discomfort due to palpitations and anxiety [3].”
Backgroundda Costa, B. R., Rutjes, A. W., Johnston, B. C., Reichenbach, S., Nüesch, E., Tonia, T., Gemperli, A., Guyatt, G. H., & Jüni, P. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys124 · Cited by 145 · cited 11×
“This was also observed in the sensitivity analysiswhereweused estimates fromBuijs et al. studywhere the comparator was clonidine (SMD-0.”
MethodInfluentialLong term use of megestrol acetate by cancer survivors for the treatment of hot flashes.
Quella, S. K., Loprinzi, C. L., Sloan, J. A., Vaught, L., DeKrey, W. L., Fischer, T., Finck, G., Pierson, N., & Pisansky, T. M. (1998) · PubMed · Cited by 143
Carpenter, J. S., Storniolo, A. M., Johns, S., Monahan, P. O., Azzouz, F., Elam, J. L., Johnson, C. S., & Shelton, R. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-124 · Cited by 143 · cited 5×
“, not significant in the funnel plot [17, 23, 29].”
BackgroundMethodSelf-citationBordeleau, L., Pritchard, K. I., Loprinzi, C. L., Ennis, M., Jugovic, O., Warr, D., Haq, R., & Goodwin, P. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9230 · Cited by 130 · cited 5×
“, not significant in the funnel plot [17, 23, 29].”
BackgroundMethodInfluentialLoibl, S., Schwedler, K., von Minckwitz, G., Strohmeier, R., Mehta, K., & Kaufmann, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl478 · Cited by 120
Boekhout, A. H., Vincent, A. D., Dalesio, O. B., van den Bosch, J., Foekema-Töns, J. H., Adriaansz, S., Sprangers, S., Nuijen, B., Beijnen, J. H., & Schellens, J. H. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1298 · Cited by 116 · cited 7×
“study were randomized to either clonidine, venlafaxine, or placebo and therefore hot flash scores were analyzed between these three arms separately [16].”
BackgroundMethodInfluentialDrug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression
Henry, N. L., Stearns, V., Flockhart, D. A., Hayes, D. F., & Riba, M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08040482 · Cited by 106 · cited 1×
“patients undergoing tamoxifen treatment [37].”
Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes
Quella, S. K., Loprinzi, C. L., Sloan, J. A., Vaught, N. L., DeKrey, W. L., Fischer, T., Finck, G., Pierson, N., & Pisansky, T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980501)82:9<1789::aid-cncr27>3.0.co;2-# · Cited by 105 · cited 1×
“menopausal symptoms among women with breast cancer [7, 8].”
BackgroundBuijs, C., Mom, C. H., Willemse, P. H. B., Boezen, H. M., Maurer, J. M., Wymenga, A. N. M., de Jong, R. S., Nieboer, P., de Vries, E. G. E., & Mourits, M. J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0138-7 · Cited by 98 · cited 6×
“provided data that were incorporated into the primary analysis [23, 24].”
MethodInfluentialManagement of menopausal symptoms in patients with breast cancer: an evidence-based approach
Hickey, M., Saunders, C. M., & Stuckey, B. G. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70316-8 · Cited by 82
Hormonal and Nonhormonal Treatment of Vasomotor Symptoms
Krause, M. S., & Nakajima, S. T. (2014) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2014.09.008 · Cited by 79 · cited 1×
“In women without breast cancer who suffer from hot flashes, hormone replacement therapy (HRT) is considered effective and remains first-line treatment [6].”
BackgroundUnjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
Binkhorst, L., Mathijssen, R. H. J., van Herk‐Sukel, M. P. P., Bannink, M., Jager, A., Wiemer, E. A. C., & van Gelder, T. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2585-z · Cited by 78 · cited 1×
“[13] However, paroxetine should be used with caution in women taking tamoxifen because of cytochrome P450 2D6 (CYP2D6) inhibition caused by drug–drug interaction, leading to reduced efficacy of tamoxifen [14, 15].”
BackgroundBreast Cancer Survivorship Issues
Stan, D., Loprinzi, C. L., & Ruddy, K. J. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.05.005 · Cited by 75
Goodwin, J. W., Green, S. J., Moinpour, C. M., Bearden, J. D., Giguere, J. K., Jiang, C. S., Lippman, S. M., Martino, S., & Albain, K. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.6179 · Cited by 65 · cited 1×
“menopausal symptoms among women with breast cancer [7, 8].”
BackgroundNewton, K. M., Carpenter, J. S., Guthrie, K. A., Anderson, G. L., Caan, B., Cohen, L. S., Ensrud, K. E., Freeman, E. W., Joffe, H., Sternfeld, B., et al. (2014) · Menopause · doi:10.1097/gme.0b013e31829337a4 · Cited by 63
Self-citationAcupuncture in the Treatment of Cancer-Related Psychological Symptoms
Haddad, N. E., & Palesh, O. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735413520181 · Cited by 57 · cited 1×
“Administration of acupuncture may not be a service that is readily available to all populations and is an operator-dependent procedure therefore results may vary [32].”
BackgroundThe Effects of Dietary Intervention on HIV Dyslipidaemia: A Systematic Review and Meta-Analysis
Stradling, C., Chen, Y., Russell, T., Connock, M. J., Thomas, G. N., & Taheri, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038121 · Cited by 52 · cited 1×
“and concealment of allocation were assessed for each study by two authors using criteria from the Cochrane Handbook (Supplementary Appendix 3) [22].”
MethodPilot Study using Gabapentin for Tamoxifen-induced Hot Flashes in Women with Breast Cancer
Pandya, K. J., Thummala, A. R., Griggs, J. J., Rosenblatt, J. D., Sahasrabudhe, D. M., Guttuso, T. J., Morrow, G. R., & Roscoe, J. A. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000010676.54597.22 · Cited by 45
Breast Cancer Survivorship: Expressed Needs of Black Women
Coggin, C., & Shaw-Perry, M. (2006) · Journal of Psychosocial Oncology · doi:10.1300/j077v24n04_06 · Cited by 25 · cited 1×
“toms, are described as intense sensations of heat associated with sweating and flushing that affect the face and chest [2].”
BackgroundWEBER, L. A., & Thacker, H. L. (2014) · Women s Health · doi:10.2217/whe.14.3 · Cited by 18 · cited 1×
“[13] However, paroxetine should be used with caution in women taking tamoxifen because of cytochrome P450 2D6 (CYP2D6) inhibition caused by drug–drug interaction, leading to reduced efficacy of tamoxifen [14, 15].”
BackgroundYamaguchi, N., Okajima, Y., Fujii, T., Natori, A., & Kobayashi, D. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1491-4 · Cited by 9 · cited 2×
“A meta-analysis reviewing the effect of venlafaxine and gabapentin also demonstrated the potential benefit of clonidine in managing hot flashes in breast cancer patients [18].”
Background
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.(118-121) Sleep disturbances may be treated with melatonin.”
BackgroundThe 2023 nonhormone therapy position statement of The North American Menopause Society
(2023) · Menopause · doi:10.1097/gme.0000000000002200 · Cited by 309
Self-citationSerotonin and Norepinephrine Reuptake Inhibitors
Shelton, R. C. (2018) · Handbook of Experimental Pharmacology · doi:10.1007/164_2018_164 · Cited by 171
Metadata
- Authors
- Ramaswami, R., Villarreal, M. D., Pitta, D. M., Carpenter, J. S., Stebbing, J., & Kalesan, B.
- Affiliations
- Imperial College London (GB)
- Columbia University (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Kalesan, Bindu
- Venue
- Breast Cancer Research and Treatment
- Published
- 2015-06-12
- Volume
- 152
- Issue
- 2
- Pages
- 231-237
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W627583589
- Cited by
- 49
- References
- 40
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 2 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 1
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14549)
- National Institute for Health and Care Research (NIHR-RP-011-053)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- venlafaxine, hot flashes, breast cancer, menopausal symptoms, tamoxifen, selective norepinephrine reuptake inhibitors, non-hormonal therapy, breast cancer survivors, quality of life
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Venlafaxine Hydrochloride, Breast Neoplasms, Female, Humans, Treatment Outcome, Disease Management, Hot Flashes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.